'$BCLI NurOwn for ALS. In the phase 2, there was no difference from placebo on ALSFRS scale. In fact, by 12 weeks follow-up, placebo patients were progressing slower. But sure, make a profit on RTT patients.' - -tweet from STAT News' Adam F

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!